Bachok Norsa'adah, Biswal Biswa Mohan, Razak Noor Hayati Abdul, Zainoon Wan Mohd Nazri Wan, Mokhtar Kasmawati, Rahman Roselinda Abdul, Abdullah Mohd Faizal, Mustafa Siti Mimi Nadiya, Noza Nawi
Biostatistics & Research Methodology Unit, School of Medical Sciences, Health Campus, Universiti Sains Malaysia, 16150 Kubang Kerian, Kelantan, Malaysia.
KPJ Ipoh Specialist Hospital, 30350 Ipoh, Perak, Malaysia.
Malays J Med Sci. 2018 Sep;25(5):79-87. doi: 10.21315/mjms2018.25.5.8. Epub 2018 Oct 30.
This quasi-clinical trial compared the effects of Oral7 and salt-soda mouthwash on the development of dental caries, salivary gland function, radiation mucositis, xerostomia and EORTC QLQ H&N C35 scores in head and neck cancer patients who underwent radiotherapy.
We included patients with histopathologically diagnosed head and neck cancers who had received radiation, with an Eastern Cooperative Oncology Group (ECOG) performance status 0-1 and age range of 15-60 years. Patients with prior radiotherapy and chemotherapy, edentulous status, total parotidectomy, sicca syndrome or on xerosis-induced medications were excluded. We assigned 15 patients each to the Oral7 and salt-soda groups.
There was no significant difference in the mean Decayed, Missing and Filling Teeth (DMFT) score between groups. Head and neck cancer patients who were on Oral7 had a significantly better quality of life than those on salt-soda in relation to the swallowing problems, social eating, mouth opening, xerostomia and illness scales. Patients who were on Oral7 had a significantly lower xerostomia score than patients on salt-soda mouthwash. Patients on Oral7 had a significantly lower mucositis score in week 5-7 compared to patients in the salt-soda group.
Oral7 showed advantages over salt-soda solution in relation to reducing xerostomia, easing radiation-induced mucositis, and improving quality of life, despite the non-significant difference in the dental caries assessment.
这项准临床试验比较了Oral7和盐苏打漱口水对接受放疗的头颈癌患者龋齿发展、唾液腺功能、放射性口腔黏膜炎、口干症以及欧洲癌症研究与治疗组织(EORTC)QLQ-H&N C35评分的影响。
我们纳入了经组织病理学诊断为头颈癌且接受过放疗的患者,其东部肿瘤协作组(ECOG)体能状态为0-1,年龄在15至60岁之间。排除曾接受过放疗和化疗、无牙状态、全腮腺切除术、干燥综合征或正在使用导致皮肤干燥药物的患者。我们将15名患者分别分配至Oral7组和盐苏打组。
两组间的龋失补牙面均数(DMFT)评分无显著差异。在吞咽问题、社交进食、张口、口干症和疾病量表方面,使用Oral7的头颈癌患者的生活质量明显优于使用盐苏打的患者。使用Oral7的患者的口干症评分明显低于使用盐苏打漱口水的患者。与盐苏打组患者相比,使用Oral7的患者在第5至7周时的口腔黏膜炎评分明显更低。
尽管在龋齿评估方面无显著差异,但在减轻口干症、缓解放射性口腔黏膜炎以及改善生活质量方面,Oral7相较于盐苏打溶液显示出优势。